Moderna And BioNTech: I Back The Former To Drive Share Price Upside In 2022

Jul. 29, 2022 2:58 PM ETBioNTech SE (BNTX), MRNA22 Comments


  • Moderna and BioNTech are the two mRNA giants behind the dominant COVID vaccines SpikeVax and Comirnaty.
  • The two companies have a great deal in common, and the share prices typically track very close to one another.
  • With Q222 earnings due soon, however, I'm favoring Moderna stock as the more likely to realize upside in 2022.
  • This is based on a new deal signed with the US government to supply an initial 66m doses of its bivalent COVID vaccine for the fall, and four potential near-term vaccine approvals.
  • BioNTech's Comirnaty vaccine still has a larger market share, but revenues are shared with Pfizer, plus BioNTech's pipeline contains no near-term commercial opportunities.
  • Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More »

Horse Race

Digital Vision./DigitalVision via Getty Images

Investment Thesis

There are many similarities between the two commercial stage pharmaceutical companies Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX).

Both are research-based companies that went public following lucrative IPOs - Moderna raising a record $604m in December 2018, at a


BioNTech & Moderna - share price performance since IPO. (TradingView)

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.

This article was written by

Edmund Ingham profile picture
Receive regular, detailed analysis focused on biotech and healthcare stocks

I write about Biotech, Pharma and Healthcare stocks and share investment tips. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. I'm on twitter @edmundingham

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MRNA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (22)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.